STOCK TITAN
  1. Home
  2. Sec-filings
  3. CURLF
  4. [6-K] Curaleaf Holdings, Inc. Current Report (Foreign Issuer)

Curaleaf (OTCQX: CURLF) appoints Four 20 Pharma founder to board

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
6-K

Rhea-AI Filing Summary

Curaleaf Holdings, Inc. filed a Form 6-K to announce the appointment of Torsten Greif to its Board of Directors. Greif is a founder of Four 20 Pharma GmbH, Curaleaf’s flagship German brand in the medical cannabis market.

The company highlights his experience in cannabis cultivation, regulatory strategy, and brand development, noting that under his leadership Four 20 Pharma completed a majority stake sale to Curaleaf. His board role is positioned as supporting Curaleaf’s European expansion and delivery of EU-GMP-certified medical cannabis across Germany and other regulated markets.

Positive

  • None.

Negative

  • None.
Commission file number 333-249081 Curaleaf Holdings Form 6-K registration reference
Four 20 Pharma team size 41 team members Employees at Four 20 Pharma GmbH based in Paderborn, Germany
Brand launch year 2020 Launch year of Four 20 Pharma’s "420NATURAL" medical cannabis brand
Annual information form date February 26, 2026 Date of Curaleaf’s latest annual information form cited for risk factors
Form month May 2026 Month and year covered by Curaleaf’s Form 6-K report
Form 6-K regulatory
"FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16"
A Form 6-K is a report that companies listed in certain countries file to provide important updates, such as financial results, corporate changes, or other significant information, to regulators and investors. It functions like an official company update or news release, helping investors stay informed about developments that could affect their investment decisions.
Board of Directors financial
"Curaleaf Announces Appointment of Torsten Greif to Board of Directors"
The Board of Directors is a group of people chosen by a company's owners to help make big decisions and oversee how the company is run. They act like a team of advisors or managers, making sure the company stays on track and meets its goals. Their choices can influence the company's success and how it grows.
EU-GMP technical
"fully EU-GMP & GDP licensed European producer and distributor of medical cannabis"
EU‑GMP is a regulatory standard that certifies pharmaceutical and related manufacturing facilities in the European Union meet strict quality and safety rules for producing medicines and medical products. For investors, an EU‑GMP certificate is like a trusted food‑safety rating for a factory: it signals lower regulatory and supply risk, access to EU markets, and greater confidence that products are consistently made to required specifications.
medical cannabis medical
"leading premium cannabis provider in Germany's emerging medical cannabis market"
Medical cannabis is the use of cannabis plant extracts or compounds such as THC and CBD as prescribed or recommended to treat symptoms or medical conditions. Think of it as a plant-based medicine that can relieve pain, nausea, muscle spasms or other symptoms where conventional drugs may not work; for investors it matters because legal status, clinical evidence, supply rules and insurance coverage determine market size, licensing value and revenue potential.
forward-looking statements regulatory
"This media advisory contains forward-looking statements and forward-looking information"
Forward-looking statements are predictions or plans that companies share about what they expect to happen in the future, like estimating sales or profits. They matter because they help investors understand a company's outlook, but since they are based on guesses and assumptions, they can sometimes be wrong.
annual information form regulatory
"contained under "Risk Factors and Uncertainties" in the Company's latest annual information form"
A company's annual information form is a comprehensive regulatory filing that lays out its business description, key assets, risks, legal matters and other background details shareholders need to understand the company’s operations. Think of it as a detailed owner’s manual or dossier that supplements financial statements, helping investors do deeper homework on how the business works and what could affect its future performance.
Form 6-K: How Foreign Companies Report to the SEC →

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER
THE SECURITIES EXCHANGE ACT OF 1934
For the month of May, 2026
Commission File Number: 333-249081
Curaleaf Holdings, Inc.
(Name of Registrant)
666 Burrard Street, Suite 1700,
Vancouver, British Columbia V6C 2X8, Canada
(Address of Principal Executive Office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F ☐    Form 40-F ☒


SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
CURALEAF HOLDINGS, INC.
(Registrant)
Date:
May 1, 2026
By:
/s/ Peter Clateman
Name:
Peter Clateman
Title:
Chief Legal Officer


EXHIBIT INDEX

Exhibit Number
Description
99.1
Press Release

Curaleaf Holdings, Inc. Investor Relations Curaleaf Announces Appointment of Torsten Greif to Board of Directors STAMFORD, Conn., May 1, 2026 /PRNewswire/ -- Curaleaf Holdings, Inc. (TSX: CURA) (OTCQX: CURLF) ("Curaleaf" or the "Company"), a leading international provider of consumer cannabis products, today announced the appointment of Torsten Greif to the Curaleaf Board of Directors. Mr. Greif is a respected entrepreneur and one of the founders of Four 20 Pharma GmbH, Curaleaf's flagship German brand. With deep expertise in cannabis cultivation, regulatory strategy, and brand development, he has been instrumental in positioning Four 20 Pharma as a leading premium cannabis provider in Germany's emerging medical cannabis market. Under his leadership, the company achieved a majority stake sale to Curaleaf, underscoring his strategic vision, cross-industry approach, and ability to find success in the evolving German cannabis market. "We're thrilled to welcome Torsten to the global Curaleaf leadership team," said Boris Jordan, Chairman and Chief Executive Officer of Curaleaf. "Torsten's vision, deep local knowledge, and proven ability to execute in complex regulatory environments will be tremendous assets as we continue to scale Curaleaf's European operations. His leadership reflects our commitment to building best-in-class cannabis businesses around the world." "I'm honored to join Curaleaf at this important stage of the company's international expansion," said Mr. Greif. "The European cannabis market is evolving rapidly, and I look forward to partnering with our talented teams to deliver high-quality, EU-GMP- certified medical cannabis to Germany and beyond. Curaleaf's global platform will enable us to accelerate innovation and contribute to the broader legitimization of cannabis in Europe." Mr. Greif's appointment reinforces Curaleaf's commitment to strategic leadership and operational excellence as the Company further integrates its European footprint and prepares for long-term growth across regulated markets. About Curaleaf Holdings Curaleaf Holdings, Inc. (TSX: CURA) (OTCQX: CURLF) ("Curaleaf") is a leading international provider of consumer products in cannabis with a mission to enhance lives by cultivating, sharing and celebrating the power of the plant. As a high-growth cannabis company known for quality, expertise and reliability, the Company and its brands, including Curaleaf, Select, Grassroots, Find, Dark Heart, and Anthem provide industry-leading service, product selection and accessibility across the medical and adult use markets. Curaleaf International is powered by a strong presence in all stages of the supply chain. Its unique distribution network throughout Europe, Canada and Australasia brings together pioneering science and research with cutting-edge cultivation, extraction and production. Curaleaf is listed on the Toronto Stock Exchange under the symbol CURA and trades on the OTCQX market under the symbol CURLF. For more information, please visit https://ir.curaleaf.com. About Four 20 Pharma GmbH Four 20 Pharma GmbH is a leading, fully EU-GMP & GDP licensed European producer and distributor of medical cannabis with industry-leading product quality and best-in-class regulatory expertise. Four 20 Pharma entered the German market with the vision to guarantee continuous patient care, and since the launch in 2020 of its "420NATURAL" brand, the company has created a steady supply chain to deliver the best possible cannabis products to its patients. The company employs 41 team members and is based in Paderborn, Germany. Forward Looking Statements This media advisory contains forward-looking statements and forward-looking information within the meaning of applicable securities laws. These statements relate to future events or future performance. All statements other than statements of historical fact may be forward–looking statements or information. Generally, forward-looking statements and information may be identified by the use of forward-looking terminology such as "plans", "expects" or "proposed", "is expected", "intends", "anticipates", or "believes", or variations of such words and phrases, or by the use of words or phrases which state that certain actions, events or results may, could, would, or might occur or be achieved. More particularly and without limitation, this news release contains forward-looking statements and information concerning an appointment to Curaleaf's Board of Directors. Such forward-looking statements and information reflect management's current beliefs and are based on assumptions made by and information currently available to the company with respect to the matter described in this new release. Forward-looking statements involve risks and uncertainties, which are based on current expectations as of the date of this release and subject to known and unknown risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Additional information about these assumptions and uncertainties is contained under "Risk Factors and Uncertainties" in the Company's latest annual information form filed on February 26, 2026, which is available under the Company's SEDAR profile at http://www.sedar.com, and in other filings that the Company has made and may make with applicable securities authorities in the future. Forward-looking statements contained herein are made only as to the date of this press release and we undertake no obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise, except as required by law. We caution investors not to place considerable reliance on the forward-looking statements contained in this press release. The Toronto Stock Exchange has not reviewed, approved or disapproved the content of this news release.

 

Investor Contact: Curaleaf Holdings, Inc. Camilo Lyon, Chief Investment Officer IR@curaleaf.com Media Contact: MATTIO Communications MattioCuraleaf@Mattio.com SOURCE Curaleaf Holdings, Inc. Additional assets available online:  Photos (1) https://ir.curaleaf.com/2026-05-01-Curaleaf-Announces-Appointment-of-Torsten-Greif-to-Board-of-Directors

 

Source: View Original Filing on SEC EDGAR

FAQ

What did Curaleaf Holdings (CURLF) announce in this Form 6-K?

Curaleaf announced the appointment of Torsten Greif to its Board of Directors. The company emphasizes his leadership at Four 20 Pharma GmbH and his experience in Germany’s medical cannabis market as it expands its European operations and integrates its international footprint.

Who is Torsten Greif and what is his background with Four 20 Pharma?

Torsten Greif is a founder of Four 20 Pharma GmbH, Curaleaf’s flagship German brand. He brings experience in cannabis cultivation, regulatory strategy, and brand development, and led Four 20 Pharma to a majority stake sale to Curaleaf in Germany’s emerging medical cannabis market.

How does Curaleaf describe the strategic importance of Torsten Greif’s appointment?

Curaleaf links Greif’s appointment to its international expansion and European growth strategy. The company cites his local knowledge and execution in complex regulatory environments as valuable for scaling Curaleaf’s European operations and supporting long-term growth across regulated cannabis markets.

What is Four 20 Pharma GmbH’s role in Curaleaf’s business?

Four 20 Pharma is described as Curaleaf’s flagship German brand and a fully EU-GMP and GDP licensed producer and distributor of medical cannabis. It focuses on continuous patient care, a steady supply chain, and premium cannabis products within Germany’s medical cannabis market.

How does Curaleaf characterize its overall business and markets served?

Curaleaf describes itself as a leading international provider of consumer cannabis products. Its brands operate across medical and adult-use markets, supported by a supply chain and distribution network spanning Europe, Canada, and Australasia focused on cultivation, extraction, production, and research.

What forward-looking statement cautions does Curaleaf include with this announcement?

Curaleaf notes the release contains forward-looking statements about the board appointment. It explains such statements involve risks and uncertainties, referring investors to the “Risk Factors and Uncertainties” section of its latest annual information form and future securities filings for more detail.

Filing Exhibits & Attachments

1 document

Press Releases